Labcorp Holdings Inc. (NYSE:LH) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Posted by Francis Steltz on Oct 6th, 2026

Shares of Labcorp Holdings Inc. (NYSE:LH – Get Free Report) have earned a consensus rating of “Moderate Buy” from the twelve research firms that are presently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $337.73.

A number of research analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $306.00 price target on shares of Labcorp in a report on Friday, July 31st. Bank of America raised their price objective on Labcorp from $300.00 to $320.00 and gave the company a “buy” rating in a research report on Monday, July 13th. UBS Group boosted their target price on shares of Labcorp from $361.00 to $380.00 and gave the stock a “buy” rating in a report on Friday, September 11th. Mizuho set a $355.00 price target on shares of Labcorp in a research report on Monday, August 10th. Finally, Morgan Stanley raised their price target on shares of Labcorp from $308.00 to $338.00 and gave the company an “overweight” rating in a report on Friday, July 31st.

Get Our Latest Analysis on LH

Insiders Place Their Bets

In related news, Director Kerrii B. Anderson sold 3,000 shares of the company’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $318.02, for a total transaction of $954,060.00. Following the transaction, the director directly owned 6,563 shares of the company’s stock, valued at $2,087,165.26. This represents a 31.37% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Amy B. Summy sold 924 shares of the stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $306.74, for a total value of $283,427.76. Following the completion of the sale, the executive vice president owned 6,956 shares of the company’s stock, valued at approximately $2,133,683.44. This trade represents a 11.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 8,593 shares of company stock valued at $2,733,295. 0.84% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Labcorp

Hedge funds have recently modified their holdings of the stock. REAP Financial Group LLC grew its position in Labcorp by 20.4% in the 4th quarter. REAP Financial Group LLC now owns 218 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 37 shares during the period. V Square Quantitative Management LLC lifted its holdings in shares of Labcorp by 1.7% in the first quarter. V Square Quantitative Management LLC now owns 2,418 shares of the medical research company’s stock valued at $645,000 after purchasing an additional 40 shares in the last quarter. Meeder Advisory Services Inc. boosted its position in shares of Labcorp by 4.5% during the first quarter. Meeder Advisory Services Inc. now owns 1,021 shares of the medical research company’s stock valued at $272,000 after buying an additional 44 shares during the last quarter. Moss Adams Wealth Advisors LLC grew its holdings in Labcorp by 3.6% during the first quarter. Moss Adams Wealth Advisors LLC now owns 1,364 shares of the medical research company’s stock worth $364,000 after buying an additional 47 shares in the last quarter. Finally, Grove Bank & Trust grew its holdings in Labcorp by 1.3% during the second quarter. Grove Bank & Trust now owns 3,719 shares of the medical research company’s stock worth $1,041,000 after buying an additional 47 shares in the last quarter. Institutional investors and hedge funds own 95.94% of the company’s stock.

Labcorp Price Performance

Shares of LH opened at $308.52 on Thursday. The company has a 50 day moving average price of $320.15 and a 200-day moving average price of $286.07. Labcorp has a fifty-two week low of $244.52 and a fifty-two week high of $341.80. The stock has a market capitalization of $25.02 billion, a PE ratio of 25.52, a PEG ratio of 1.75 and a beta of 0.87. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.53 and a current ratio of 1.80.

Labcorp (NYSE:LH – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The medical research company reported $4.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.78 by $0.21. The company had revenue of $3.73 billion for the quarter, compared to analyst estimates of $3.71 billion. Labcorp had a net margin of 6.99% and a return on equity of 16.74%. Labcorp’s revenue was up 5.8% compared to the same quarter last year. During the same period last year, the company posted $4.35 earnings per share. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. Equities analysts predict that Labcorp will post 18.32 earnings per share for the current fiscal year.

Labcorp Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 28th were paid a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 0.9%. The ex-dividend date was Friday, August 28th. Labcorp’s dividend payout ratio (DPR) is 23.82%.

About Labcorp

(Get Free Report)

Labcorp (NYSE:LH), formally Laboratory Corporation of America Holdings, is a global life sciences and laboratory services company headquartered in Burlington, North Carolina. The company provides diagnostic testing, drug development services and technology-enabled laboratory solutions to healthcare providers, pharmaceutical and biotechnology companies, government agencies and consumers.

Its diagnostics business offers routine and specialty laboratory testing, including testing related to oncology, women’s health, infectious diseases, genetics and genomics.